A detailed history of China Universal Asset Management Co., Ltd. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 23,420 shares of APLS stock, worth $657,165. This represents 0.08% of its overall portfolio holdings.

Number of Shares
23,420
Previous 14,260 64.24%
Holding current value
$657,165
Previous $547,000 23.4%
% of portfolio
0.08%
Previous 0.08%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$28.84 - $41.15 $264,174 - $376,934
9,160 Added 64.24%
23,420 $675,000
Q2 2024

Jul 19, 2024

SELL
$38.07 - $59.71 $339,660 - $532,732
-8,922 Reduced 38.49%
14,260 $547,000
Q1 2024

Apr 29, 2024

BUY
$55.39 - $72.47 $524,654 - $686,435
9,472 Added 69.09%
23,182 $1.36 Million
Q4 2023

May 21, 2024

SELL
$37.14 - $64.82 $351,790 - $613,975
-9,472 Reduced 40.86%
13,710 $820,000
Q4 2023

Jan 23, 2024

BUY
$37.14 - $64.82 $396,729 - $692,407
10,682 Added 352.77%
13,710 $821,000
Q3 2023

May 21, 2024

BUY
$23.65 - $89.22 $16,247 - $61,294
687 Added 29.35%
3,028 $115,000
Q3 2023

Oct 30, 2023

BUY
$23.65 - $89.22 $16,247 - $61,294
687 Added 29.35%
3,028 $115,000
Q2 2023

May 21, 2024

SELL
$76.68 - $93.31 $1,917 - $2,332
-25 Reduced 1.06%
2,341 $213,000
Q2 2023

Jul 27, 2023

SELL
$76.68 - $93.31 $1,917 - $2,332
-25 Reduced 1.06%
2,341 $213,000
Q1 2023

May 21, 2024

BUY
$46.59 - $66.96 $57,911 - $83,231
1,243 Added 110.69%
2,366 $156,000
Q1 2023

Apr 27, 2023

BUY
$46.59 - $66.96 $57,911 - $83,231
1,243 Added 110.69%
2,366 $156,000
Q4 2022

May 21, 2024

SELL
$43.24 - $61.04 $953,831 - $1.35 Million
-22,059 Reduced 95.16%
1,123 $58,000
Q4 2022

Jan 31, 2023

BUY
$43.24 - $61.04 $4,064 - $5,737
94 Added 9.14%
1,123 $58,000
Q3 2022

Oct 21, 2022

BUY
$44.76 - $69.66 $46,058 - $71,680
1,029 New
1,029 $70,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.08B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.